T-cell receptor on CD8+ T lymphocyte (TCR (CD8+ T cell))

The **T-cell receptor (TCR) on CD8+ T lymphocytes** is a heterodimeric receptor typically composed of α and β chains that recognize antigenic peptides presented by MHC-I molecules. This recognition, enhanced by the CD8 co-receptor, triggers intracellular signaling cascades involving kinases such as Lck and ZAP-70, leading to activation, proliferation, and cytotoxic effector functions by the T cell[2][3][6]. TCR-CD8+ T cell interactions are critical for immune surveillance against viruses and tumors and are exploited in many cancer immunotherapy strategies (e.g., adoptive cell transfer, CAR-T, immune checkpoint blockade)[1]. The TCR also plays roles in thymic selection and immune tolerance, with dysregulation implicated in autoimmunity and immunodeficiency[3][5]. For structured data extraction, the TCR as expressed on CD8+ T cells (sometimes called cytotoxic T lymphocytes) is an unequivocally important immune receptor with clear disease and therapeutic relevance.

Other names

TCR (CD8+ T cell)CD8+ T cell receptorCytotoxic T cell receptor

Immunomodulation: drugs or biologics can enhance or inhibit TCR signaling to increase cytotoxicity or tolerance Signal blockade: inhibitors target kinases (e.g., Lck, ZAP-70) downstream of TCR to suppress activation TCR engagement: monoclonal antibodies can block or mimic antigen presentation